Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 627 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR 27-Year-Old Thought She Was Injured Falling Off A Horse, But Then... May 13, 2019 Artificial Intelligence Expedites Brain Tumor Diagnosis during Surgery February 12, 2020 Young Woman Considers Service Dog A Crucial Ally In Her Battle... July 20, 2020 ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European... March 10, 2023 Load more HOT NEWS Breastfeeding Duration Could Influence Breast Cancer Risk, Study Shows A bug in the system – the difficulties of linking the... Mom Gives ‘Elf On The Shelf’ A Wheelchair For Daughter With... FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer
